Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum AB    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB

(SOBI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
154.3(c) 156.25(c) 153.4(c) 150.15(c) 149.85 Last
670 742 1 242 640 906 524 1 368 753 675 820 Volume
+0.59% +1.26% -1.82% -2.12% -0.20% Change
More quotes
Financials
Sales 2020 15 359 M 1 801 M 1 801 M
Net income 2020 2 793 M 327 M 327 M
Net Debt 2020 10 695 M 1 254 M 1 254 M
P/E ratio 2020 15,9x
Yield 2020 -
Sales 2021 16 478 M 1 932 M 1 932 M
Net income 2021 3 406 M 399 M 399 M
Net Debt 2021 5 567 M 653 M 653 M
P/E ratio 2021 13,1x
Yield 2021 -
Capitalization 44 279 M 5 167 M 5 192 M
EV / Sales 2020 3,58x
EV / Sales 2021 3,03x
Nbr of Employees 1 471
Free-Float 62,6%
More Financials
Company
Swedish Orphan Biovitrum AB is specialized in the development, manufacturing and marketing of therapeutic products intended for the treatment of rare diseases (hemophilia, inflammatory and autoimmune illnesses, hereditary metabolic diseases, etc.). The turnover per source of income can be broken down as follows: - sales of products (87.3%); - royalties (9.6%); - sales of sub-contracted manufactured products... 
Sector
Pharmaceuticals
Calendar
12/05Präsentation
More about the company
Notations Surperformance© of Swedish Orphan Biovitrum AB
Trading Rating : Investor Rating :
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB
11/19SWEDISH ORPHAN BIOVITRUM : Sobi and Apellis announce first patient dosed in pote..
AQ
11/16SWEDISH ORPHAN BIOVITRUM : CHMP has adopted a negative opinion for emapalumab in..
AQ
11/13SWEDISH ORPHAN BIOVITRUM : The CHMP has adopted a negative opinion for emapaluma..
AQ
11/06SWEDISH ORPHAN BIOVITRUM : Strong Sobi presence at American Society of Hematolog..
AQ
11/04SWEDISH ORPHAN BIOVITRUM : Sobi launch Doptelet® (avatrombopag) in Europe
AQ
10/29SWEDISH ORPHAN BIOVITRUM : Favourable paediatric data results in Alprolix ® prod..
AQ
10/23SWEDISH ORPHAN BIOVITRUM : Invitation to the Sobi Capital Markets Day 2020
AQ
10/22SWEDISH ORPHAN BIOVITRUM : Sobi publishes report for the third quarter 2020
AQ
10/21GSK to launch late-stage testing of syncytial virus vaccine
RE
10/17SWEDISH ORPHAN BIOVITRUM : Emapalumab's efficacy confirmed by sensitivity analys..
AQ
10/12SWEDISH ORPHAN BIOVITRUM : Sobi announces topline phase 3 data of avatrombopag f..
AQ
10/09Sobi shares fall 17% as Avatrombopag study fails to meet primary endpoint
RE
10/09SWEDISH ORPHAN BIOVITRUM : Sobi announces topline phase 3 data of avatrombopag f..
AQ
10/08SWEDISH ORPHAN BIOVITRUM : Invitation, Presentation of Sobi's Q3 2020 results
AQ
10/07SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q3 2020 results
AQ
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB
10/09SWEDISH ORPHAN BIOVITRUM AB : chute après son étude sur l’Avatrombopag
07/22AVIS D'ANALYSTES DU JOUR : Altice, AXA, Givaudan, Ipsen, Logitech, Proximus, Som..
07/17AVIS D'ANALYSTES DU JOUR : BNP Paribas, Boiron, Givaudan, Heineken, Swedish Orph..
07/13SWEDISH ORPHAN BIOVITRUM : publication des résultats semestriels
07/13SWEDISH ORPHAN BIOVITRUM : Veröffentlichung des Halbjahresergebnisses
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB
Duration : Period :
Swedish Orphan Biovitrum AB Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 221,50 SEK
Last Close Price 150,15 SEK
Spread / Highest target 76,5%
Spread / Average Target 47,5%
Spread / Lowest Target 16,6%
EPS Revisions
Managers
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Henrik Stenqvist Chief Financial Officer
Anne Marie de Jonge Schuermans Head-Technical Operations
Ravi M. Rao Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM AB-2.82%5 167
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273